NF-κB polymorphisms had an impact on cancer risks, and carriers of specific NF-κB variants might benefit from NSAIDs in cancer chemoprevention (Chang et al., 2009; Seufert et al., 2013). The gene discussed is NFKB1; the disease is cancer.